Business Wire

Tenpoint Therapeutics Launches with $70 Million Series A Financing to Reverse Vision Loss Through Engineered Cell-Based Therapeutics and In Vivo Reprogramming

LONDON--(BUSINESS WIRE)--Tenpoint Therapeutics (“Tenpoint”), a biotechnology company pursuing vision-restoring engineered cell-based therapeutics and in vivo reprogramming to address degenerative ...
Business Wire

Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines

LONDON & SEATTLE--(BUSINESS WIRE)--Tenpoint Therapeutics, Limited (“Tenpoint”) and Visus Therapeutics, Inc., (“Visus”) announce today the completion of their merger to create an entirely new chapter ...
Healio

Tenpoint Therapeutics launches with $70 million in Series A financing

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Tenpoint Therapeutics has launched with a $70 million ...
Yahoo Finance

Tenpoint Therapeutics Ltd. Announces FDA Acceptance of New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia

LONDON & SEATTLE, June 03, 2025--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd. ("Tenpoint"), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate ...
Morningstar

Tenpoint Therapeutics Ltd. to Participate in Upcoming Investor Conferences in August

Tenpoint Therapeutics, Ltd., a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that the Company ...